11 results about "Hydrolase inhibitor" patented technology

A first aspect of the invention relates to a method of treating or preventing tissue damage, or treating or preventing tissue destruction, in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of a soluble epoxide hydrolase (sEH) inhibitor. A further aspect of the invention relates to a method of treating or preventing leishmaniasis in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of a soluble epoxide hydrolase inhibitor.

The present application relates to an aromatic-substituted benzimidazole compound, a cis-trans isomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof. The present application also relates to a method for preparing an aromatic-substituted benzimidazole compound, and the use of the aromatic-substituted benzimidazole compound as a soluble epoxide hydrolase inhibitor. The aromatic-substituted benzimidazole compounds described herein exhibit extremely high inhibitory activity against soluble epoxide hydrolase, with IC 50 values in the nanomolar range or even lower.

The application belongs to the field of new use of drugs, and more particularly relates to application of 3-Deazaadenosine in preparation of a therapeutic drug for treating hypertrophic scars. 3-Deazaadenosine is an S-adenosylhomocysteine hydrolase inhibitor, and has antiviral, anti-inflammatory and other activities. Experiments show that the compound can significantly reduce the modification level of m6A in fibroblasts in hypertrophic scar tissue, inhibit the proliferation and migration of fibroblasts, promote the apoptosis of fibroblasts, and also can reduce the expression levels of Collagen I, Collagen III and alpha-SMA in fibroblasts. Therefore, the compound can be used for preparing a drug for relieving or treating hypertrophic scars, and has important clinical application value.

The invention belongs to the field of biological medicines, and relates to a DDX10 fusion protein and a preparation method thereof. The amino acid sequence of the DDX10 fusion protein is as shown in SEQ ID NO: 1. The method comprises the following steps: 1) amplifying a nucleic acid sequence for coding the DDX10 fusion protein; 2) cloning the nucleic acid sequence into a prokaryotic expression vector; (3) transforming the prokaryotic expression vector into an E. coli strain; 4) inducing expression of the DDX10 fusion protein; and 5) purifying the DDX10 fusion protein. The DDX10 fusion protein disclosed by the invention has ATP hydrolase activity and helicase activity, the method disclosed by the invention is easy for large-scale production and can be used for high-throughput screening of helicase or ATP hydrolase inhibitors, and an expression system of the DDX10 fusion protein is simple.

Disclosed are a long-acting oral pharmaceutical comprising a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and use thereof. Specifically, disclosed is a long-acting oral pharmaceutical formulation comprising a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, adjuvants, or excipients. The long-acting oral pharmaceutical formulation is suitable for administration at intervals of once every one week or longer, making it suitable for long-term administration in the treatment of chronic anemia.

A first aspect of the invention relates to a method of treating or preventing tissue damage, or treating or preventing tissue destruction, in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of a soluble epoxide hydrolase (sEH) inhibitor. A further aspect of the invention relates to a method of treating or preventing leishmaniasis in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of a soluble epoxide hydrolase inhibitor.

The present invention provides novel heterocyclic compounds having the general formula (I) wherein X, Y, A, B, C and R 1 as described herein; compositions comprising the compounds; methods of making the compounds; and methods of using the compounds as soluble epoxide hydrolase inhibitors.(I)

The disclosure provides compounds, in part, compounds of Formula I or Formula II and their use in treating medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical compositions and methods of making compounds of the disclosure are provided. The compounds are contemplated to be modulators, e.g., inhibitors, of cyclic ADP ribose hydrolase (CD38).

The invention belongs to the technical field of biological medicines, and particularly relates to application of an O-GlcNAc glycosyl hydrolase inhibitor in preparation of a medicine for treating depression caused by opioid withdrawal. Experimental research shows that after being used for a long time, the opioids are abstinged, so that the glycosylation modification of dopaminergic neurons O-GlcNAc in a covered region on the abdominal side of a mouse is reduced, and the phenotypes of pleasant sensation loss and despair-like depression are caused. Intracranial sustained release and intraperitoneal injection of the O-GlcNAc glycosyl hydrolase inhibitor MK-8719 can recover the glycosylation modification level of dopaminergic neurons O-GlcNAc, can significantly improve pleasant sensation loss and despair symptoms caused by withdrawal of opioid analgesic drugs, and has an anti-depression curative effect. Therefore, the O-GlcNAc glycosyl hydrolase inhibitor MK-8719 can effectively reduce pleasant sensation loss and despair-like behaviors, the inhibition effect is clear in target and remarkable in effect, and the O-GlcNAc glycosyl hydrolase inhibitor MK-8719 can be applied to preparation of drugs for treating depression caused by withdrawal of opioid analgesic drugs.